Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
NCT04984837Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Oct 2021
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of lacutamab in peripheral T-cell lymphoma (PTCL), sponsored by LYSARC. Started Oct 2021; status: active, not recruiting.
02
Drugs
lacutamab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04984837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984837.